JP2018131439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018131439A5 JP2018131439A5 JP2018021874A JP2018021874A JP2018131439A5 JP 2018131439 A5 JP2018131439 A5 JP 2018131439A5 JP 2018021874 A JP2018021874 A JP 2018021874A JP 2018021874 A JP2018021874 A JP 2018021874A JP 2018131439 A5 JP2018131439 A5 JP 2018131439A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- compound
- infected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 241000711549 Hepacivirus C Species 0.000 claims 17
- 229940125904 compound 1 Drugs 0.000 claims 8
- 229940125782 compound 2 Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 4
- 208000003322 Coinfection Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 230000001447 compensatory effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/431,906 US11484534B2 (en) | 2013-03-14 | 2017-02-14 | Methods for treating HCV |
| US15/431,906 | 2017-02-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018131439A JP2018131439A (ja) | 2018-08-23 |
| JP2018131439A5 true JP2018131439A5 (enExample) | 2021-04-01 |
Family
ID=61192811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018021874A Pending JP2018131439A (ja) | 2017-02-14 | 2018-02-09 | Ｈｃｖを処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3360555A1 (enExample) |
| JP (1) | JP2018131439A (enExample) |
| CN (1) | CN108421029A (enExample) |
| AU (1) | AU2018201011A1 (enExample) |
| BR (1) | BR102018002956A2 (enExample) |
| CA (1) | CA2994496A1 (enExample) |
| MX (1) | MX2018001905A (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1742913A1 (en) * | 2003-12-11 | 2007-01-17 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| DK2618831T3 (en) | 2010-09-21 | 2016-04-04 | Enanta Pharm Inc | Macrocyclic prolinafledte HCV serine protease inhibitors |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| DE202012012956U1 (de) * | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| NZ719137A (en) * | 2013-03-14 | 2017-11-24 | Abbvie Inc | Combination of two antivirals for treating hepatitis c |
| WO2014152635A1 (en) * | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
| BR112016022976A8 (pt) * | 2014-04-02 | 2021-07-20 | Abbvie Inc | métodos para o tratamento de hcv |
| JP6808660B2 (ja) * | 2015-07-08 | 2021-01-06 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置するための方法 |
-
2018
- 2018-02-09 JP JP2018021874A patent/JP2018131439A/ja active Pending
- 2018-02-09 CA CA2994496A patent/CA2994496A1/en active Pending
- 2018-02-12 EP EP18156337.0A patent/EP3360555A1/en not_active Withdrawn
- 2018-02-12 AU AU2018201011A patent/AU2018201011A1/en not_active Abandoned
- 2018-02-13 CN CN201810149405.XA patent/CN108421029A/zh active Pending
- 2018-02-14 MX MX2018001905A patent/MX2018001905A/es unknown
- 2018-02-15 BR BR102018002956A patent/BR102018002956A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2004509061A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| JP2011519364A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| JP2016513703A5 (enExample) | ||
| JP2013522302A5 (enExample) | ||
| JP2003526662A5 (enExample) | ||
| JP2004534769A5 (enExample) | ||
| RU2010113976A (ru) | Применение glp-1 в качестве терапевтического средства | |
| JP2010503396A5 (enExample) | ||
| RU2010114047A (ru) | Применение нейропептида af человека в качестве терапевтического средства | |
| SI2968302T1 (en) | Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV | |
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| JP2015517528A5 (enExample) | ||
| RU2005126412A (ru) | Сор1 для лечения воспалительных заболеваний кишечника | |
| RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
| JP2013518124A5 (enExample) | ||
| RU2010153688A (ru) | Режим дозирования телапревира | |
| NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
| JPWO2019200005A5 (enExample) | ||
| JP2018131439A5 (enExample) | ||
| RU2013120345A (ru) | Новые способы лечения инфекции, вызванной вирусом гепатита с |